Literature DB >> 11782904

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

Patrick Poulin1, Frank-Peter Theil.   

Abstract

In drug discovery and nonclinical development the volume of distribution at steady state (V(ss)) of each novel drug candidate is commonly determined under in vivo conditions. Therefore, it is of interest to predict V(ss) without conducting in vivo studies. The traditional description of V(ss) corresponds to the sum of the products of each tissue:plasma partition coefficient (P(t:p)) and the respective tissue volume in addition to the plasma volume. Because data on volumes of tissues and plasma are available in the literature for mammals, the other input parameters needed to estimate V(ss) are the P(t:p)'s, which can potentially be predicted with established tissue composition-based equations. In vitro data on drug lipophilicity and plasma protein binding are the input parameters used in these equations. Such a mechanism-based approach would be particularly useful to provide first-cut estimates of V(ss) prior to any in vivo studies and to explore potential unexpected deviations between sets of predicted and in vivo V(ss) data, when the in vivo data become available during the drug development process. The objective of the present study was to use tissue composition-based equations to predict rat and human V(ss) prior to in vivo studies for 123 structurally unrelated compounds (acids, bases, and neutrals). The predicted data were compared with in vivo data obtained from the literature or at Roche. Overall, the average ratio of predicted-to-experimental rat and human V(ss) values was 1.06 (SD = 0.817, r = 0.78, n = 147). In fact, 80% of all predicted values were within a factor of two of the corresponding experimental values. The drugs can therefore be separated into two groups. The first group contains 98 drugs for which the predicted V(ss) were within a factor of two of those experimentally determined (average ratio of 1.01, SD = 0.39, r = 0.93, n = 118), and the second group includes 25 other drugs for which the predicted and experimental V(ss) differ by a factor larger than two (average ratio of 1.32, SD = 1.74, r = 0.42, n = 29). Thus, additional relevant distribution processes were neglected in predicting V(ss) of drugs of the second group. This was true especially in the case of some cationic-amphiphilic bases. The present study is the first attempt to develop and validate a mechanistic distribution model for predicting rat and human V(ss) of drugs prior to in vivo studies. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782904     DOI: 10.1002/jps.10005

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  137 in total

1.  In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values.

Authors:  Mario Lobell; Vinothini Sivarajah
Journal:  Mol Divers       Date:  2003       Impact factor: 2.943

2.  Prediction of in vivo tissue distribution from in vitro data. 3. Correlation between in vitro and in vivo tissue distribution of a homologous series of nine 5-n-alkyl-5-ethyl barbituric acids.

Authors:  Peter Ballard; David E Leahy; Malcolm Rowland
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

Review 3.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening.

Authors:  Daniel M Rotroff; Barbara A Wetmore; David J Dix; Stephen S Ferguson; Harvey J Clewell; Keith A Houck; Edward L Lecluyse; Melvin E Andersen; Richard S Judson; Cornelia M Smith; Mark A Sochaski; Robert J Kavlock; Frank Boellmann; Matthew T Martin; David M Reif; John F Wambaugh; Russell S Thomas
Journal:  Toxicol Sci       Date:  2010-07-16       Impact factor: 4.849

Review 5.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

6.  Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios.

Authors:  Ivelina Gueorguieva; Ivan A Nestorov; Susan Murby; Sophie Gisbert; Brent Collins; Kelly Dickens; Judith Duffy; Ziad Hussain; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

7.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

8.  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Authors:  Nikunjkumar Patel; Oliver Hatley; Alexander Berg; Klaus Romero; Barbara Wisniowska; Debra Hanna; David Hermann; Sebastian Polak
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

9.  Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.

Authors:  Greg M Thurber; Thomas Reiner; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  Mol Cancer Ther       Date:  2014-02-19       Impact factor: 6.261

10.  Drug Distribution Part 2. Predicting Volume of Distribution from Plasma Protein Binding and Membrane Partitioning.

Authors:  Ken Korzekwa; Swati Nagar
Journal:  Pharm Res       Date:  2016-12-13       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.